Korsana Biosciences, Inc.

Korsana Biosciences, Inc.

KRSA - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.28M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Korsana Biosciences, Inc.Korsana Biosciences, Inc.-0.1--13%4.5-
$51.20

Target Price by Analysts

61.8% upsideKorsana Biosciences Target Price DetailsTarget Price
$0.38

Current Fair Value

98.8% downside

Overvalued by 98.8% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$4.28 Million
Enterprise Value$-450,669,148.00
Earnings per Share$-7.07
Beta1.84
Outstanding Shares135,256

Return

Return on Equity-13.32%ROE
Return on Assets-11.29%
Return on Invested Capital-12.94%

Valuation & Multiples

P/E Ratio-0.09P/E Ratio
PEG0PEG
Price to Sales4.52Price to Sales
Price to Book Ratio0.01Price to Book Ratio
Enterprise Value to Revenue-299.3
Enterprise Value to EBIT5.67
Enterprise Value to Net Income8
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 11, 2026
EPS Estimate
-$0.85
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 29, 2027
EPS Estimate
-$0.89
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Cyclerion Therapeutics Inc

1 employees
CEO: Jonathan Violin

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules ...